Complex Formation Between VEGFR2 and the β-Adrenoceptor

Overview

Journal Cell Chem Biol

Publisher Cell Press

Specialty Biochemistry

Date 2019 Apr 9

PMID 30956148

Citations 18

Authors

Laura E Kilpatrick

Diana C Alcobia

Carl W White

Chloe J Peach

Jackie R Glenn

Kris Zimmerman

Alexander Kondrashov

Kevin D G Pfleger

Rachel Friedman Ohana

Matthew B Robers

Keith V Wood

Erica K Sloan

Jeanette Woolard

Stephen J Hill

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) is an important mediator of endothelial cell proliferation and angiogenesis via its receptor VEGFR2. A common tumor associated with elevated VEGFR2 signaling is infantile hemangioma that is caused by a rapid proliferation of vascular endothelial cells. The current first-line treatment for infantile hemangioma is the β-adrenoceptor antagonist, propranolol, although its mechanism of action is not understood. Here we have used bioluminescence resonance energy transfer and VEGFR2 genetically tagged with NanoLuc luciferase to demonstrate that oligomeric complexes involving VEGFR2 and the β-adrenoceptor can be generated in both cell membranes and intracellular endosomes. These complexes are induced by agonist treatment and retain their ability to couple to intracellular signaling proteins. Furthermore, coupling of β-adrenoceptor to β-arrestin2 is prolonged by VEGFR2 activation. These data suggest that protein-protein interactions between VEGFR2, the β-adrenoceptor, and β-arrestin2 may provide insight into their roles in health and disease.

Citing Articles

Extracellular bimolecular fluorescence complementation for investigating membrane protein dimerization: a proof of concept using class B GPCRs.

Garelja M, Alexander T, Walker C, Hay D Biosci Rep. 2024; 44(10).

PMID: 39361899 PMC: 11499381. DOI: 10.1042/BSR20240449.

Mechano-sensitivity of β2-adrenoceptors enhances constitutive activation of cAMP generation that is inhibited by inverse agonists.

Cullum S, Platt S, Dale N, Isaac O, Wragg E, Soave M Commun Biol. 2024; 7(1):417.

PMID: 38580813 PMC: 10997663. DOI: 10.1038/s42003-024-06128-2.

CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans.

White C, Platt S, Kilpatrick L, Dale N, Abhayawardana R, Dekkers S Sci Signal. 2024; 17(828):eabl3758.

PMID: 38502733 PMC: 7615768. DOI: 10.1126/scisignal.abl3758.

The cancer-immune dialogue in the context of stress.

Ma Y, Kroemer G Nat Rev Immunol. 2023; 24(4):264-281.

PMID: 37833492 DOI: 10.1038/s41577-023-00949-8.

Detecting and measuring of GPCR signaling - comparison of human induced pluripotent stem cells and immortal cell lines.

Chen G, Obal D Front Endocrinol (Lausanne). 2023; 14:1179600.

PMID: 37293485 PMC: 10244570. DOI: 10.3389/fendo.2023.1179600.

References

Luttrell L, Daaka Y, Lefkowitz R . Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol. 1999; 11(2):177-83. DOI: 10.1016/s0955-0674(99)80023-4. View

Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C . EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 2000; 402(6764):884-8. DOI: 10.1038/47260. View

Laporte S, Oakley R, Holt J, Barak L, Caron M . The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem. 2000; 275(30):23120-6. DOI: 10.1074/jbc.M002581200. View

Luttrell L, Roudabush F, Choy E, Miller W, Field M, Pierce K . Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A. 2001; 98(5):2449-54. PMC: 30158. DOI: 10.1073/pnas.041604898. View

Thuringer D, Maulon L, Frelin C . Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem. 2001; 277(3):2028-32. DOI: 10.1074/jbc.M109493200. View

Feoktistov I, Goldstein A, Ryzhov S, Zeng D, Belardinelli L, Voyno-Yasenetskaya T . Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res. 2002; 90(5):531-8. DOI: 10.1161/01.res.0000012203.21416.14. View

Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

Mercier J, Salahpour A, Angers S, Breit A, Bouvier M . Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem. 2002; 277(47):44925-31. DOI: 10.1074/jbc.M205767200. View

Baker J, Hall I, Hill S . Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist. Br J Pharmacol. 2003; 139(2):232-42. PMC: 1573863. DOI: 10.1038/sj.bjp.0705287. View

10.

Hart S, Fischer O, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L . GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem. 2005; 386(9):845-55. DOI: 10.1515/BC.2005.099. View

11.

Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J, Taieb A . Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358(24):2649-51. DOI: 10.1056/NEJMc0708819. View

12.

Kocan M, See H, Seeber R, Eidne K, Pfleger K . Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J Biomol Screen. 2008; 13(9):888-98. DOI: 10.1177/1087057108324032. View

13.

Gibson D, Young L, Chuang R, Venter J, Hutchison 3rd C, Smith H . Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009; 6(5):343-5. DOI: 10.1038/nmeth.1318. View

14.

Dosch D, Ballmer-Hofer K . Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. FASEB J. 2009; 24(1):32-8. DOI: 10.1096/fj.09-132670. View

15.

Ferrara N . VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2010; 20(4):158-63. DOI: 10.1684/ecn.2009.0170. View

16.

Liebmann C . EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol. 2010; 331(2):222-31. DOI: 10.1016/j.mce.2010.04.008. View

17.

Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K . S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 2010; 151(7):2994-3005. DOI: 10.1210/en.2009-1387. View

18.

Park S, Kang J, Jeong K, Lee J, Han J, Choi W . Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer. 2010; 128(10):2306-16. DOI: 10.1002/ijc.25589. View

19.

Sloan E, Priceman S, Cox B, Yu S, Pimentel M, Tangkanangnukul V . The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010; 70(18):7042-52. PMC: 2940980. DOI: 10.1158/0008-5472.CAN-10-0522. View

20.

Rasmussen S, Choi H, Fung J, Pardon E, Casarosa P, Chae P . Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature. 2011; 469(7329):175-80. PMC: 3058308. DOI: 10.1038/nature09648. View